---
title: "Moody’s upgrades Teva to investment-grade Baa3 rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295533397.md"
description: "Moody’s upgraded Teva Pharmaceutical Industries Ltd.’s corporate credit rating to investment-grade Baa3 from Ba1, with a stable outlook. The agency cited earnings-driven debt reduction, improving margins, solid free cash flow, and revenue diversity as key factors. Moody’s anticipates further debt reduction over the next 12 to 18 months."
datetime: "2026-08-11T12:03:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295533397.md)
  - [en](https://longbridge.com/en/news/295533397.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295533397.md)
generator: "portal-rs"
---

# Moody’s upgrades Teva to investment-grade Baa3 rating

-   Moody’s upgraded Teva’s corporate credit rating to Baa3 from Ba1, lifting it to investment grade with a stable outlook. \* Moody’s cited earnings-led debt reduction, improving margins, solid free cash flow, revenue diversity. \* Agency expects further debt reduction over the next 12 to 18 months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110800OMX\_\_\_\_\_CNEWS\_EN\_GNW1001257062\_en) on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md)
- [MCO.US](https://longbridge.com/en/quote/MCO.US.md)

## Related News & Research

- [Teva, Trump Administration Announce Intent To Reach Agreement On Affordable Medicines](https://longbridge.com/en/news/297556815.md)
- [Teva, Trump administration pursue Medicaid drug pricing agreement under GENEROUS framework](https://longbridge.com/en/news/297556474.md)
- [Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study](https://longbridge.com/en/news/297800772.md)
- [TEVA: TEV ‘408 significantly prevented gluten-induced intestinal damage in celiac disease Phase 2a study](https://longbridge.com/en/news/297776333.md)
- [Teva bids to buy BioXcel’s IGALMI asset for USD 57.5 million upfront, up to USD 67.5 million more](https://longbridge.com/en/news/297306157.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**